GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2023 is now available on the company’s website, www.isofolmedical.com.
Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from the company’s in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company’s drug candidate arfolitixorin. Isofol has therefore decided to continue the development of arfolitixorin and is intensifying preparations for a possible start of a minor clinical study.
Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has decided to appoint Roger Tell as acting CEO for the company, effective immediately.
Gothenburg, Sweden, June 21, 2023 – Isofol Medical AB (publ) announces today that Thomas Andersson, at his own request, has chosen to resign as Chief Executive Officer of the company.
Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who today has decided to resign as Board Director and instead will take a new role as senior advisor to the company.
Today on May 3, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed.
GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com.
Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated a preclinical research collaboration with the Norwegian biotech company Oncosyne AS, to evaluate the effect of the drug candidate arfolitixorin in different doses combined with the cancer drug 5-FU, among others. This is an important step in the company´s previously communicated strategy to re-evaluate possible future tracks for arfolitixorin and to maximize the opportunities to take the drug candidate further toward potential market approval.
GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for the first quarter of 2023 on Wednesday, May 3, 2023. On the same day, Isofol invites investors, analysts, and media to an audiocast. The company´s chairman and CEO gives an update with a subsequent question and answer session.
GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2022 are now available, in Swedish, on the company’s website, www.isofolmedical.com.
